• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Arrowhead Pharmaceuticals Reports Fiscal 2023 Third Quarter Results

    8/7/23 4:01:00 PM ET
    $ARWR
    $GSK
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ARWR alert in real time by email

    Conference Call and Webcast Today, August 7, 2023 at 4:30 p.m. ET

    Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced financial results for its fiscal third quarter ended June 30, 2023. The company is hosting a conference call today, Aug. 7, 2023, at 4:30 p.m. ET to discuss the results.

    Webcast and Conference Call and Details

    Investors may access a live audio webcast on the Company's website at http://ir.arrowheadpharma.com/events.cfm. A replay of the webcast will be available approximately two hours after the conclusion of the call.

    For analysts that wish to participate in the conference call, please register at https://register.vevent.com/register/BIcd0f2b791a4f4cdd97a1c78e09086106. Once registered, you will receive the dial-in number and a personalized PIN code that will be required to access the call.

    Selected Recent Events

    • Hosted a Research & Development Day to discuss progress towards the company's "20 in 25" goal to grow its pipeline of RNAi therapeutics that leverage the proprietary Targeted RNAi Molecule (TRiMTM) platform to a total of 20 clinical stage or marketed products in the year 2025. Key updates included:
      • New Phase 1 clinical data on ARO-RAGE showing a continued dose response in healthy volunteers with a single inhaled dose of 184 mg achieving mean knockdown of 90% and a maximum of 95% in bronchoalveolar lavage fluid (BALF)
      • Serum sRAGE reductions in asthma patients consistent with effects seen in healthy volunteers at the 44 mg dose, the only dose level with results currently available in asthma patient cohorts
      • TRiMTM platform for intrathecal administration for central nervous system (CNS) delivery demonstrates 90-95% dose-dependent mRNA knockdown in disease-relevant spinal cord and cortex brain regions in non-human primates
      • TRiMTM platform for adipose tissue delivery achieved up to 98% knockdown and maintained greater than 85% knockdown over 31 weeks
      • TRiMTM dimer platform for delivery to hepatocytes achieved equivalent or better knockdown of two separate target genes with longer duration than monomer mixture
    • Completed enrollment of the global PALISADE Phase 3 clinical trial evaluating ARO-APOC3 for the treatment of familial chylomicronemia syndrome. The company anticipates that the primary portion of the study will be complete in the second quarter of 2024 with a data readout shortly thereafter
    • Presented interim data from the ongoing Phase 2 GATEWAY clinical study of ARO-ANG3 in patients with homozygous familial hypercholesterolemia at the 91st European Atherosclerosis Society Congress showing that ARO-ANG3 achieved 44-48% mean reductions in LDL-C on top of continued standard of care
    • Presented updated results from the Phase 2 SEQUOIA clinical study of investigational fazirsiran (TAK-999/ARO-AAT) for the treatment of liver disease associated with alpha-1 antitrypsin deficiency at the European Association for the Study of the Liver (EASL) Congress 2023
    • Filed an application to initiate a Phase 1 clinical trial of ARO-SOD1, an RNAi-based investigational medicine designed to reduce expression of superoxide dismutase 1 (SOD1) in the CNS as a potential treatment for patients with amyotrophic lateral sclerosis (ALS) caused by SOD1 mutations. ARO-SOD1 is the first therapeutic candidate designed for delivery to the CNS to enter clinical studies that leverages the TRiMTM platform
    • Filed an application to initiate a Phase 1/2 clinical trial of ARO-DUX4, the company's investigational RNAi therapeutic being developed as a potential treatment for patients with facioscapulohumeral muscular dystrophy (FSHD). ARO-DUX4 is the first clinical candidate utilizing the TRiMTM platform to target disease associated genes in skeletal muscle
    • Earned a $30 million milestone payment from GSK (NYSE:GSK) following the start of GSK's Phase 2b trial of GSK4532990, formerly called ARO-HSD, an investigational RNAi therapeutic for the treatment of patients with non-alcoholic steatohepatitis (NASH)
    • Earned a $40 million milestone payment from Takeda (NYSE:TAK) after the first patient was dosed in the Phase 3 REDWOOD clinical study of fazirsiran

    Selected Fiscal 2023 Third Quarter Financial Results

    Three Months Ended June 30,

    OPERATING SUMMARY

     

    2023

     

     

    2022

     

    (unaudited)

    Revenue

    $

    15,825

    $

    32,412

    Operating Expenses:

     

     

     

    Research and development

     

    94,757

     

    72,180

    General and administrative expenses

     

    23,771

     

     

    33,141

    Total Operating Expenses

     

    118,528

     

    105,321

    Operating loss

     

    (102,703)

     

     

    (72,909)

    Interest income

     

    4,172

     

     

    1,240

     

    Interest expense

     

    (5,158)

     

     

    -

    Other, net

     

    306

     

    (377)

     

    Loss before income tax expense and noncontrolling interest

     

    (103,383)

     

     

    (72,046)

     

    Income tax expense

     

    742

     

     

    -

    Net loss before noncontrolling interest

     

    (104,125)

     

     

    (72,046)

    Net loss attributable to noncontrolling interest, net of tax

     

    (1,179)

     

    -

    Net loss attributable to Arrowhead Pharmaceuticals, Inc.

    $

    (102,946)

     

    $

    (72,046)

     

    Net loss per share attributable to Arrowhead Pharmaceuticals, Inc. - Diluted

    $

    (0.96)

     

    $

    (0.68)

    Weighted-average shares used in calculating - Diluted

     

    107,004

     

    105,753

     

    FINANCIAL POSITION SUMMARY

    June 30,

    2023

     

    September 30,

    2022

     

    (unaudited)

    Cash, cash equivalents and restricted cash

    $

    105,334

    $

    108,005

    Short-term investments

     

    346,369

     

     

    268,391

    Long-term investments

     

    42,758

     

    105,872

    Total cash resources (cash and investments)

     

    494,461

     

     

    482,268

    Other assets

     

    301,395

     

    209,671

    Total Assets

    $

    795,856

     

    $

    691,939

     

    Current deferred revenue

    $

    16,905

     

    $

    74,099

    Long-term deferred revenue

     

    -

     

    55,950

    Other liabilities

     

    396,966

     

     

    143,551

    Total Liabilities

    $

    413,871

    $

    273,600

     

     

     

     

    Total Arrowhead Pharmaceuticals, Inc. Stockholders' Equity

    $

    364,830

    $

    398,520

    Noncontrolling Interest

     

    17,155

     

     

    19,819

    Total Noncontrolling Interest and Stockholders' Equity

     

    381,985

     

    418,339

    Total Liabilities, Noncontrolling Interest and Stockholders' Equity

    $

    795,856

     

    $

    691,939

     

    Shares Outstanding

     

    107,102

     

     

    105,960

    About Arrowhead Pharmaceuticals

    Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead's RNAi-based therapeutics leverage this natural pathway of gene silencing.

    For more information, please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts.

    Safe Harbor Statement under the Private Securities Litigation Reform Act:

    This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this release except for historical information may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "expect," "believe," "anticipate," "hope," "intend," "plan," "project," "could," "estimate," "continue," "target," "forecast" or "continue" or the negative of these words or other variations thereof or comparable terminology are intended to identify such forward-looking statements. In addition, any statements that refer to projections of our future financial performance, trends in our business, expectations for our product pipeline or product candidates, including anticipated regulatory submissions and clinical program results, prospects or benefits of our collaborations with other companies, or other characterizations of future events or circumstances are forward-looking statements. These forward-looking statements include, but are not limited to, statements about the initiation, timing, progress and results of our preclinical studies and clinical trials, and our research and development programs; our expectations regarding the potential benefits of the partnership, licensing and/or collaboration arrangements and other strategic arrangements and transactions we have entered into or may enter into in the future; our beliefs and expectations regarding milestone, royalty or other payments that could be due to or from third parties under existing agreements; and our estimates regarding future revenues, research and development expenses, capital requirements and payments to third parties. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of numerous factors and uncertainties, including the impact of the ongoing COVID-19 pandemic on our business, the safety and efficacy of our product candidates, decisions of regulatory authorities and the timing thereof, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, the enforcement of our intellectual property rights, and the other risks and uncertainties described in our most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and other documents filed with the Securities and Exchange Commission from time to time. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

    Source: Arrowhead Pharmaceuticals, Inc.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20230807767868/en/

    Get the next $ARWR alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ARWR
    $GSK
    $TAK

    CompanyDatePrice TargetRatingAnalyst
    GSK plc
    $GSK
    6/3/2025Buy → Hold
    Berenberg
    GSK plc
    $GSK
    4/15/2025$35.25Neutral
    Exane BNP Paribas
    Takeda Pharmaceutical Company Limited
    $TAK
    4/2/2025Equal-Weight → Overweight
    Morgan Stanley
    GSK plc
    $GSK
    2/12/2025Equal-Weight
    Morgan Stanley
    GSK plc
    $GSK
    11/15/2024Buy → Hold
    Deutsche Bank
    GSK plc
    $GSK
    11/12/2024$53.00 → $39.50Buy → Hold
    Jefferies
    GSK plc
    $GSK
    10/31/2024Buy → Neutral
    Guggenheim
    GSK plc
    $GSK
    7/8/2024Buy → Neutral
    UBS
    More analyst ratings

    $ARWR
    $GSK
    $TAK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Hamilton James C sold $200,000 worth of shares (10,000 units at $20.00), decreasing direct ownership by 4% to 262,122 units (SEC Form 4)

    4 - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Issuer)

    8/15/25 5:59:02 PM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Apel Daniel Joseph claimed ownership of 101,200 shares (SEC Form 3)

    3 - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Issuer)

    8/12/25 5:49:57 PM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Anzalone Christopher Richard sold $1,533,337 worth of shares (141,122 units at $10.87), decreasing direct ownership by 3% to 3,921,255 units (SEC Form 4)

    4 - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Issuer)

    4/11/25 6:20:07 PM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARWR
    $GSK
    $TAK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Lu Hongbo bought $82,990 worth of shares (3,000 units at $27.66), increasing direct ownership by 10% to 33,680 units (SEC Form 4)

    4 - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Issuer)

    3/20/24 7:06:58 PM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARWR
    $GSK
    $TAK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    GlaxoSmithKline downgraded by Berenberg

    Berenberg downgraded GlaxoSmithKline from Buy to Hold

    6/3/25 7:26:51 AM ET
    $GSK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Exane BNP Paribas initiated coverage on GlaxoSmithKline with a new price target

    Exane BNP Paribas initiated coverage of GlaxoSmithKline with a rating of Neutral and set a new price target of $35.25

    4/15/25 12:40:46 PM ET
    $GSK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Takeda Pharma upgraded by Morgan Stanley

    Morgan Stanley upgraded Takeda Pharma from Equal-Weight to Overweight

    4/2/25 8:46:19 AM ET
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARWR
    $GSK
    $TAK
    SEC Filings

    View All

    SEC Form 6-K filed by GSK plc

    6-K - GSK plc (0001131399) (Filer)

    8/22/25 9:29:40 AM ET
    $GSK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by GSK plc

    6-K - GSK plc (0001131399) (Filer)

    8/21/25 11:13:39 AM ET
    $GSK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by GSK plc

    6-K - GSK plc (0001131399) (Filer)

    8/21/25 6:27:12 AM ET
    $GSK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARWR
    $GSK
    $TAK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Arrowhead Pharmaceuticals Redeems Approximately $50 Million of Arrowhead Stock and Will Receive Approximately $50 Million in Cash in Satisfaction of Milestone from Sarepta Therapeutics

    - Arrowhead has elected to receive approximately $50 million worth of Arrowhead common stock from Sarepta, which will be placed into treasury and reduce the number of Arrowhead shares outstanding - The remainder of the recently earned $100 million milestone, or approximately $50 million, will be received in cash - Sarepta's remaining holdings of Arrowhead stock were sold today in a separate negotiated block trade Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that it has elected to receive approximately $50 million worth of Arrowhead common stock and approximately $50 million in cash from Sarepta Therapeutics, satisfying the payment of a $100 million milestone owed to A

    8/13/25 4:10:00 PM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arrowhead Pharmaceuticals Reports Fiscal 2025 Third Quarter Results

    - Conference Call and Webcast Today, August 7, 2025, at 4:30 p.m. ET Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced financial results for its fiscal 2025 third quarter ended June 30, 2025. The Company is hosting a conference call today, August 7, 2025, at 4:30 p.m. ET to discuss the results. "Arrowhead continues to achieve strong execution in discovery, clinical and regulatory, and business development. Our pipeline has become quite mature, with four Arrowhead discovered candidates currently in pivotal Phase 3 studies. In addition, our commercial buildout is designed to make us launch ready on day one, should plozasiran receive regulatory approval on the November 18, 2025

    8/7/25 4:01:00 PM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arrowhead Subsidiary Visirna Sells Rights to Hypertriglyceridemia Candidate Plozasiran in Greater China to Sanofi

    - Sanofi to pay $130 million upfront and up to $265 million in potential regulatory milestones to Visirna Therapeutics, a majority-owned subsidiary of Arrowhead, which was previously granted rights to investigational plozasiran in Greater China - Sanofi will receive an exclusive license to develop and commercialize investigational plozasiran in Greater China from Visirna Therapeutics, offering potential treatment to people living with elevated triglycerides Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced the signing of an asset purchase agreement between Sanofi and Visirna Therapeutics, a majority-owned subsidiary of Arrowhead created to develop and commercialize four of A

    8/1/25 6:30:00 AM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARWR
    $GSK
    $TAK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Arrowhead Pharmaceuticals Inc.

    SC 13G - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Subject)

    11/14/24 9:38:25 AM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by GSK plc

    SC 13G/A - GSK plc (0001131399) (Subject)

    11/12/24 4:32:59 PM ET
    $GSK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Arrowhead Pharmaceuticals Inc.

    SC 13G/A - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Subject)

    10/16/24 9:15:20 AM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARWR
    $GSK
    $TAK
    Leadership Updates

    Live Leadership Updates

    View All

    GSK and Lifetime® launch original movie to raise awareness about the impact of meningitis

    Pretty Hurts, a new Lifetime Original Movie brought to you by GSK, informs Lifetime's mom audience about meningococcal disease, known as meningitis Partnership is part of GSK's Ask2BSure campaign, which encourages parents of teens and young adults ages 16-23 to start a conversation with their teen's doctor about meningitis and vaccination Hollywood moms of teens, Alyson Hannigan and Sarah Michelle Gellar, team up with GSK and Ask2BSure to help raise awareness GSK plc (LSE/NYSE:GSK) today announced its sponsorship of Pretty Hurts, a gripping new Lifetime Original Movie and the latest extension of GSK's Ask2BSure public health campaign. Premiering on June 28, 2025, at 8 p.m. ET/7 p.m.

    5/9/25 9:00:00 AM ET
    $GSK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arrowhead Pharmaceuticals Appoints Daniel Apel as Chief Financial Officer

    Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that, effective May 13, 2025, Arrowhead's Chief Financial Officer, Ken Myszkowski, will retire after 16 years of service to the company and will be succeeded by Daniel Apel, who has been appointed as the company's new Chief Financial Officer. Mr. Myszkowski will continue to serve as an employee adviser to assist and facilitate an effective transition. "Ken has been a valuable member of the Arrowhead team, and he retires at a time of great financial strength for the company. The finance organization that Ken built over the years is very capable and provides strong support to our ambitious development and commercialization plans.

    4/15/25 4:00:00 PM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    GeminiBio Appoints Mike Stella to Board

    Strengthening Board with Industry Veterans Gemini Bioproducts, LLC ("GeminiBio"), a biopharma and advanced therapy raw materials supplier, and a portfolio company of BelHealth Investment Partners, LLC ("BelHealth"), a Fort Lauderdale-based healthcare private equity firm, announced today the appointment of Michael Stella to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250218608576/en/Mike Stella, CEO of Ascend Advanced Therapies, joins the Board at GeminiBio to provide strategic leadership in the fields of cell and gene therapy contract development and manufacturing. (Photo: Business Wire) GeminiBio prov

    2/18/25 9:00:00 AM ET
    $AMGN
    $GSK
    $JNJ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Industrial Machinery/Components

    $ARWR
    $GSK
    $TAK
    Financials

    Live finance-specific insights

    View All

    Arrowhead Pharmaceuticals Redeems Approximately $50 Million of Arrowhead Stock and Will Receive Approximately $50 Million in Cash in Satisfaction of Milestone from Sarepta Therapeutics

    - Arrowhead has elected to receive approximately $50 million worth of Arrowhead common stock from Sarepta, which will be placed into treasury and reduce the number of Arrowhead shares outstanding - The remainder of the recently earned $100 million milestone, or approximately $50 million, will be received in cash - Sarepta's remaining holdings of Arrowhead stock were sold today in a separate negotiated block trade Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that it has elected to receive approximately $50 million worth of Arrowhead common stock and approximately $50 million in cash from Sarepta Therapeutics, satisfying the payment of a $100 million milestone owed to A

    8/13/25 4:10:00 PM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arrowhead Pharmaceuticals Reports Fiscal 2025 Third Quarter Results

    - Conference Call and Webcast Today, August 7, 2025, at 4:30 p.m. ET Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced financial results for its fiscal 2025 third quarter ended June 30, 2025. The Company is hosting a conference call today, August 7, 2025, at 4:30 p.m. ET to discuss the results. "Arrowhead continues to achieve strong execution in discovery, clinical and regulatory, and business development. Our pipeline has become quite mature, with four Arrowhead discovered candidates currently in pivotal Phase 3 studies. In addition, our commercial buildout is designed to make us launch ready on day one, should plozasiran receive regulatory approval on the November 18, 2025

    8/7/25 4:01:00 PM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Takeda Announces First-Quarter FY2025 Results With Significant Late-Stage Pipeline Progression

    Revenue Decline of 3.7% at Constant Exchange Rate (CER); 8.4% Decline at Actual Exchange Rates (AER) as VYVANSE® Generic Erosion Impacts Revenue in Line With Company Expectations Core Operating Profit Decline of 11.9% at CER, Primarily Reflecting Generic Erosion Reported Operating Profit Increase of 11.0% at AER, Reflecting Lower YoY Impairment and Restructuring Expenses Positive Results from Two Pivotal Phase 3 Studies of Oveporexton in Narcolepsy Type 1 Reinforce Continued Momentum in Late-Stage Pipeline No Change to Full-Year Outlook Announced in May Takeda ((4502, NYSE:TAK) today announced earnings results for the first quarter of fiscal year 2025 (three months ended Jun

    7/30/25 2:41:00 AM ET
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care